FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Medical Devices

Quality System and Other Issues in CardioQuip Inspection

FDA warns College Station, TX-based CardioQuip about multiple violations in its manufacture of a cardiac heater-cooler device in various configuration...

Federal Register

FDA Withdraws Potassium Aminobenzoate Products

Federal Register notice: FDA announces that all outstanding hearing requests regarding certain potassium aminobenzoate products have been withdrawn an...

Recommendations to Improve Medical Supply Chain

A National Academies committee recommends seven ways government and other stakeholders can improve the resilience of the U.S. medical products supply ...

Medical Devices

Pearl 510(k) Cleared for AI X-ray Reader

FDA clears a Pearl 510(k) for its Second Opinion, an artificial intelligence radiologic detection aid intended to help dentists identify numerous comm...

Human Drugs

Generic Drug Research Focuses on Complex Drugs: Report

CDER posts its FY 2021 GDUFA Science and Research Report that updates stakeholders on the development of innovative methodologies and more efficient t...

Human Drugs

FDA Wants Quality Metrics Comments

FDA asks stakeholders to comment on proposed changes to the drug quality metrics reporting program that has been tested in two pilots.

Medical Devices

Axeda Cybersecurity Vulnerability Found

FDA says the computer software company PTC is recommending actions to be taken by medical device manufacturers who use PTCs Axeda agent or desktop ser...

Human Drugs

Court Order Against Salud Natural Entrepreneur

An Illinois federal court approves a permanent injunction against Waukegan, IL-based dietary supplement maker Salud Natural Entrepreneur.

Mallinckrodt Pays $260 Million on False Claims Violations

Mallinckrodt agrees to pay $260 million to resolve allegations that it violated the False Claims Act by knowingly underpaying Medicaid rebates due for...

Human Drugs

FDA Denies 2013 Anticholinergic Label Petition

FDA denies a petition seeking a stronger Warning on labeling of OTC drugs with anticholinergic effects.